-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

286 Cereblon Deficiency Leads to Alteration in c-Myc Regulated Genes, Increased Glucose Uptake and Resistance to JQ1 Bromodomain Inhibition

Lymphocytes, Lymphocyte Activation and Immunodeficiency, including HIV and Other Infections
Program: Oral and Poster Abstracts
Type: Oral
Session: 203. Lymphocytes, Lymphocyte Activation and Immunodeficiency, including HIV and Other Infections: T and B Lymphocyte Biology
Sunday, December 6, 2015: 5:15 PM
W315, Level 3 (Orange County Convention Center)

Matthew S Beatty, PhD1*, Rebecca S Hesterberg, BA2, Ying Han, MD3*, Eric Padron, M.D.1,4, Adam W Mailloux, PhD1*, Sean Yoder, M.S5*, Anjali M Rajadhyaksha, PhD6*, Alan F. List, MD7,8 and Pearlie K Epling-Burnette, PhD1

1Department of Immunology, Moffitt Cancer Center and Research Institute, Tampa, FL
2Immunology Program, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL
3Biotherapy Department, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China
4Division of Hematologic Malignancies, Moffitt Cancer Center and Research Institute, Tampa, FL
5Molecular Genomics Core Facility, Moffit Cancer Center and Research Institute, Tampa, FL
6Pediatric Neurology, Weill Cornell Medical College, New York, NY
7Department of Hematologic Malignancies, Moffitt Cancer Center and Research Institute, Tampa, FL
8Division of Clinical Science, Moffitt Cancer Center and Research Institute, Tampa, FL

Background: Immunomodulatory drugs (IMiDs), including thalidomide and its analogs, are highly effective for the treatment of both non-del5q and del5q Myelodysplastic Syndrome (MDS) and other hematological cancers. IMiDs have also been shown to play an additional role as a potent T-cell stimulant for cancer therapy. The first identified target of IMiDs is cereblon, an E3 ubiquitin ligase substrate receptor. From crystal structure analysis of human and murine crbn/ddb1 bound to lenalidomide or thalidomide, IMiDs bind to a conserved hydrophobic pocket of crbn called the thalidomide-binding domain. To explore possible mechanisms of crbn regulation of immune response, we studied immune regulation in cereblon deficient mice (crbn-/-), which have increased T-cell proliferation and cytokine production.

Results: We have previously shown that purified T-cells from crbn deficient mice have greater immune activation with increased proliferation and pro-inflammatory cytokines, including IL-2, IFNγ, and TNFα, when compared to wild-type T-cells. Additionally crbn-/- T-cells mount a greater alloimmune response in vivo. To determine the molecular effects of crbn deficiency on T-cell response following activation, we analyzed gene expression by Affymetrix microarray in wild-type and crbn-/- purified T-cells before and 12 hours following activation with anti-CD3 and anti-CD28 antibodies. Based on hierarchal clustering, the majority of gene expression changes were driven by T-cell activation. To explore the effect of crbn deficiency on T-cell activation, we compared genes from wild type and crbn-/- T-cells that showed a 2-fold (FDR<0.05) expression change following activation. Wild-type and crbn-/- T-cells shared an overlapping set of 3795 probesets. However, 798 and 3226 probesets were upregulated 2-fold only in wild-type and crbn-/- T-cells respectively following activation. Gene ontology analysis of the crbn-/- only subset showed enrichment for metabolic processes. Utilizing GSEA analysis, we identified c-Myc as an enriched transcription factor that regulates genes found in the crbn-/- only gene subset. Although no differences were seen in c-Myc expression by qRT-PCR, the c-Myc protein was increased in crbn-/- T-cells at earlier times of activation and prolonged through 48hrs post-activation compared to wild-type T-cells that showed a shorter duration of Myc activation. Indicative of differences in c-Myc activation, the c-Myc responsive gene known as SLC2A1, encoding glucose transporter 1 (or GLUT1), was elevated in crbn-/- T-cells compared to WT T-cells. Consistent with the role of GLUT1 in the facilitation of glucose transport across plasma membranes, crbn-/- T-cells showed an increased uptake of 2-NBDG, a fluorescent glucose analog. Treatment of the cells with JQ-1, an inhibitor of BET bromodomains and a suppressor of c-Myc expression, resulted in a decrease in wild-type T-cell proliferation while crbn-/- T-cells showed less sensitivity to JQ1 inhibition of proliferation.

Conclusions: Our results indicate that cereblon deficiency results in an increased immune response in T-cells. Analyzing gene expression pattern differences between wild-type and crbn-/- T-cells, we identified c-Myc as a possible driver of this phenotype. Interestingly, c-Myc regulates the metabolic switch from oxidative phosphorylation to glycolysis and expression levels of c-Myc can effect proliferation and cytokine production, both of which are upregulated in crbn-/- T-cells. The prolonged expression of c-Myc protein could be responsible for the increase in Glut1 expression, glucose uptake, and resistance to JQ1. Overall, cereblon may negatively regulate c-Myc and the metabolic switch to glycolysis, resulting in crbn-/- T-cells having an increased glycolytic phenotype following activation.

Disclosures: List: Celgene Corporation: Honoraria , Research Funding .

*signifies non-member of ASH